Kurs pSivida Corp. Nasdaq

Aktien

09.08.16	PSivida : Primary Endpoint Met in pSivida's Utilization Study of New Medidur™ Inserter with Smaller Diameter Needle
14.07.16	PSivida : Investigator-Sponsored Phase 2 Study Results Show pSivida's Medidur® Fully Controlled Uveitis for Two Years with No Recurrence of Disease While Visual Acuity Continued to Improve
02.05.16	PSivida : Medidur for Posterior Uveitis Granted Orphan Drug Designation in Europe
28.09.15	PSivida : Announces NDA for Medidur™ Now Planned Using Six-Month Efficacy Data from Both Phase III Trials; FDA Concurs
14.09.15	PSivida : CEO to Present at Ladenburg Thalmann 2015 Healthcare Conference September 29, 2015

1 Tag

-0.87%

Zu einer Liste hinzufügen 0 ausgewählt Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein Einloggen Anmeldung	%	% 5 Tage	Perf. 1 Jahr	Perf. 3 Jahre	Marktkap.($)
PSIVIDA CORP.	-0.87%	-2.40%	-	-	0
WUXI APPTEC CO., LTD.	-4.83%	+3.51%	+55.00%	+63.79%	66.7 Mrd.
ARGENX SE	+0.02%	+1.07%	+11.72%	+75.63%	56.88 Mrd.
LONZA GROUP AG	-1.34%	+2.98%	+25.08%	+100.18%	56.53 Mrd.
BEONE MEDICINES AG	+5.09%	+9.89%	+27.19%	+105.85%	46.49 Mrd.
IQVIA HOLDINGS INC.	+2.62%	+1.68%	+29.16%	+35.86%	44.8 Mrd.
REVOLUTION MEDICINES, INC.	+8.24%	+0.51%	+215.16%	+794.74%	41.59 Mrd.
CELLTRION, INC.	-1.86%	+10.13%	+28.14%	+55.48%	35.35 Mrd.
GENMAB A/S	-2.97%	-9.84%	+90.91%	+73.49%	33.29 Mrd.
INSMED INCORPORATED	+5.19%	+1.62%	-39.69%	+368.87%	25.1 Mrd.
Durchschnitt	+0.93%	+2.65%	+49.18%	+185.99%	45.19 Mrd.
Nach Marktkapitalisierung gewichteter Durchschnitt	+0.65%	+3.07%	+49.90%	+165.88%

Beschäftigte

Sektor